naratuximab emtansine (Debio 1562)

non-Hodgkin lymphoma

naratuximab emtansine (Debio 1562), an anti-CD37 antibody-drug conjugate (ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL). naratuximab emtansine (Debio 1562) demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is currently in phase IIb in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status.

Press Releases

All Press Releases